

해외 바이오의약품 임상 현황 (2020.10.05~2020.10.11)

한국바이오의약품협회, 2020.10.13
출처: ClinicalTrials.gov

○ 미국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04441047	Universal Anti-Viral Vaccine for Healthy Elderly Adults	Virus Diseases	Drug: AlloStim	Immunovative Therapies, Ltd. Mirror Biologics, Inc.	Phase 1 Phase 2
NCT04108481	Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	Colorectal Cancer Metastatic Colon Cancer Metastatic Colorectal Cancer Rectal Cancer Liver Metastasis Colon Cancer Colo-rectal Cancer Colorectal Adenocarcinoma Colorectal Neoplasms Liver Metastases Colorectal Carcinoma	Drug: Durvalumab Radiation: Yttrium-90 RadioEmbolization	University of Iowa Biocompatibles UK Ltd AstraZeneca	Phase 1 Phase 2
NCT04522817	CLBS119 for Repair of COVID-19 Induced Pulmonary Damage	Covid-19	Biological: CLBS119	Caladrius Biosciences, Inc.	Phase 1
NCT04498377	Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19	Covid19	Biological: F-652 Biological: Placebo	Generon (Shanghai) Corporation Ltd.	Phase 2
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3

○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04575181	A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine	Diabetes Mellitus, Type 2	Drug: NNC0268-0965 Drug: Insulin glargine Drug: Placebo (NNC0268-0965) Drug: Placebo (insulin glargine)	Novo Nordisk A/S	Phase 1

○ 중국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03181087	Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars	Uterine Scar	Other: Umbilical cord MSCs	Maternal and Child Health Hospital of Foshan	Phase 1
NCT04581473	Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection	Gastric Adenocarcinoma Pancreatic Cancer Gastroesophageal Junction Adenocarcinoma	Drug: CT041 autologous CAR T-cell injection	Carsgen Therapeutics, Ltd. Beijing Cancer Hospital Fudan University	Phase 1 Phase 2
NCT04532229	Nimotuzumab in Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children	Diffuse Intrinsic Pontine Glioma	Drug: Nimotuzumab+CRT(concurrent IMRT and TMZ)	Biotech Pharmaceutical Co., Ltd.	Phase 2
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04222114	Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis	Stomach Neoplasms	Drug: Catumaxomab Drug: The treatment of investigator choice	LintonPharm Co.,Ltd.	Phase 3

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3